{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:24:52Z","timestamp":1783977892947,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00584 PI22\/01404"],"award-info":[{"award-number":["PI19\/00584 PI22\/01404"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00021"],"award-info":[{"award-number":["PMP22\/00021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11739-024-03813-2","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T09:25:54Z","timestamp":1731921954000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic treatment with SGLT-2 inhibitors is associated with ICU admission and disease severity in patients with diabetic ketoacidosis: a propensity score\u2013matched cohort study"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-0483","authenticated-orcid":false,"given":"Fernando","family":"Sebastian-Valles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sara","family":"Tapia-Sanchiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Navas-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lopez-Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Carrillo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sager La Ganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Raposo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gonz\u00e1lez-Casta\u00f1ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Von Wernitz Teleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"del Arco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Alfonso","family":"Arranz-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00592-023-02181-1","volume":"61","author":"K Takahashi","year":"2024","unstructured":"Takahashi K, Uenishi N, Sanui M et al (2024) Clinical profile of patients with diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome in Japan: a multicenter retrospective cohort study. Acta Diabetol 61:117\u2013126. https:\/\/doi.org\/10.1007\/s00592-023-02181-1","journal-title":"Acta Diabetol"},{"key":"3813_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107797","author":"KK Dhatariya","year":"2019","unstructured":"Dhatariya KK (2019) Defining and characterising diabetic ketoacidosis in adults. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2019.107797","journal-title":"Diabetes Res Clin Pract"},{"key":"3813_CR3","doi-asserted-by":"publisher","unstructured":"Benoit SR, Zhang Y, Geiss LS, et al (2018) Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality \u2014 United States, 2000\u20132014. MMWR Morb Mortal Wkly Rep 67:362\u2013365. https:\/\/doi.org\/10.15585\/mmwr.mm6712a3","DOI":"10.15585\/mmwr.mm6712a3"},{"key":"3813_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.endonu.2016.06.003","volume":"63","author":"I Romera","year":"2016","unstructured":"Romera I, Ampudia-Blasco FJ, P\u00e9rez A et al (2016) Eficacia y seguridad de empagliflozina en combinaci\u00f3n con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. Endocrinol Nutr 63:519\u2013526. https:\/\/doi.org\/10.1016\/j.endonu.2016.06.003","journal-title":"Endocrinol Nutr"},{"key":"3813_CR5","doi-asserted-by":"publisher","unstructured":"Pujante P, Ares J, Maci\u00e1 C, et al Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes Type 2. Medicina Cl\u00ednica. https:\/\/doi.org\/10.1016\/j.medcli.2018.09.019","DOI":"10.1016\/j.medcli.2018.09.019"},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc21-1584","volume":"45","author":"A Palanca","year":"2022","unstructured":"Palanca A, van Nes F, Pardo F et al (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with Type 1 diabetes: a european two-center experience. Diabetes Care 45:650\u2013658. https:\/\/doi.org\/10.2337\/dc21-1584","journal-title":"Diabetes Care"},{"key":"3813_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101501","volume":"50","author":"M Dur\u00e1n-Mart\u00ednez","year":"2024","unstructured":"Dur\u00e1n-Mart\u00ednez M, Azriel S, Doulatram-Gamgaram VK et al (2024) Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: the Dapa-ON multicenter retrospective study. Diabetes Metab 50:101501. https:\/\/doi.org\/10.1016\/j.diabet.2023.101501","journal-title":"Diabetes Metab"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcjd.2021.04.006","volume":"46","author":"M Colacci","year":"2022","unstructured":"Colacci M, Fralick J, Odutayo A, Fralick M (2022) Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with Type 2 Diabetes: a systematic review and meta-analysis. Can J Diabetes 46:10-15.e2. https:\/\/doi.org\/10.1016\/j.jcjd.2021.04.006","journal-title":"Can J Diabetes"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","volume":"41","author":"EJ Meyer","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D (2018) SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care 41:e47\u2013e49. https:\/\/doi.org\/10.2337\/dc17-1721","journal-title":"Diabetes Care"},{"key":"3813_CR10","doi-asserted-by":"crossref","unstructured":"Palmer BF, Clegg DJ (2021) Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol","DOI":"10.2215\/CJN.17621120"},{"key":"3813_CR11","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc23-1903","volume":"47","author":"AG Hayes","year":"2023","unstructured":"Hayes AG, Raven LM, Viardot A et al (2023) SGLT2 inhibitor-induced ketoacidosis in a patient without diabetes. Diabetes Care 47:e4\u2013e5. https:\/\/doi.org\/10.2337\/dc23-1903","journal-title":"Diabetes Care"},{"key":"3813_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with Type 1 Diabetes treated with Sodium-Glucose Cotransporter (SGLT) inhibitors. Diabetes Care 42:1147\u20131154. https:\/\/doi.org\/10.2337\/dc18-2316","journal-title":"Diabetes Care"},{"key":"3813_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2337\/dci19-0008","volume":"42","author":"JI Wolfsdorf","year":"2019","unstructured":"Wolfsdorf JI, Ratner RE (2019) SGLT inhibitors for Type 1 Diabetes: proceed with extreme caution. Diabetes Care 42:991\u2013993. https:\/\/doi.org\/10.2337\/dci19-0008","journal-title":"Diabetes Care"},{"key":"3813_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1464-5491.2011.03246.x","volume":"28","author":"MW Savage","year":"2011","unstructured":"Savage MW, Dhatariya KK, Kilvert A et al (2011) Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 28:508\u2013515. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03246.x","journal-title":"Diabet Med"},{"key":"3813_CR15","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.2337\/dc06-9916","volume":"29","author":"AE Kitabchi","year":"2006","unstructured":"Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA (2006) Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29:2739\u20132748. https:\/\/doi.org\/10.2337\/dc06-9916","journal-title":"Diabetes Care"},{"key":"3813_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.3263","volume":"21","author":"JA Rassen","year":"2012","unstructured":"Rassen JA, Shelat AA, Myers J et al (2012) One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 21:69\u201380. https:\/\/doi.org\/10.1002\/pds.3263","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3813_CR17","unstructured":"Rothman KJ, Lash TL, Greenland S (2008) Modern epidemiology \/ Kenneth J. Rothman; Sander Greenland; Timothy L. Lash, 3rd. ed. Lippincott Williams & Wilkins, Philadelphia"},{"key":"3813_CR18","unstructured":"Team RC (2013) R: A language and environment for statistical computing"},{"key":"3813_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman Bernard","year":"2015","unstructured":"Bernard Zinman, Christoph Wanner, Lachin John M et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"3813_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal Bruce","year":"2017","unstructured":"Bruce Neal, Vlado Perkovic, Mahaffey Kenneth W et al (2017) Canagliflozin and cardiovascular and renal events in Type 2 Diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"3813_CR21","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"3813_CR22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"3813_CR23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/dom.14335","volume":"23","author":"A Haidar","year":"2021","unstructured":"Haidar A, Yale J-F, Lovblom LE et al (2021) Reducing the need for carbohydrate counting in Type 1 Diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: a randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obes Metab 23:1272\u20131281. https:\/\/doi.org\/10.1111\/dom.14335","journal-title":"Diabetes Obes Metab"},{"key":"3813_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/dia.2021.0542","volume":"24","author":"J Garcia-Tirado","year":"2022","unstructured":"Garcia-Tirado J, Farhy L, Nass R et al (2022) Automated insulin delivery with SGLT2i combination therapy in Type 1 Diabetes. Diabetes Technol Ther 24:461\u2013470. https:\/\/doi.org\/10.1089\/dia.2021.0542","journal-title":"Diabetes Technol Ther"},{"key":"3813_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","volume":"128","author":"Y Wang","year":"2017","unstructured":"Wang Y, Desai M, Ryan PB et al (2017) Incidence of diabetic ketoacidosis among patients with Type 2 Diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract 128:83\u201390. https:\/\/doi.org\/10.1016\/j.diabres.2017.04.004","journal-title":"Diabetes Res Clin Pract"},{"key":"3813_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51184","volume":"15","author":"R Haddadin","year":"2023","unstructured":"Haddadin R, Aboujamra D, Iraninezhad H (2023) Sodium-glucose cotransporter-2 inhibitor-induced euglycemic diabetic ketoacidosis in a Type 2 Diabetic patient. Cureus 15:e51184. https:\/\/doi.org\/10.7759\/cureus.51184","journal-title":"Cureus"},{"key":"3813_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110236","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Zhao F, Zhang Y et al (2023) Risk factors of dapagliflozin-associated diabetic ketosis\/ketoacidosis in patients with type 2 diabetes mellitus: a matched case-control study. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2023.110236","journal-title":"Diabetes Res Clin Pract"},{"key":"3813_CR28","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB et al (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1687\u20131693. https:\/\/doi.org\/10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"3813_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/dom.14271","volume":"23","author":"T Danne","year":"2021","unstructured":"Danne T, Edelman S, Frias JP et al (2021) Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index \u2265 27 kg\/m2. Diabetes Obes Metab 23:854\u2013860. https:\/\/doi.org\/10.1111\/dom.14271","journal-title":"Diabetes Obes Metab"},{"key":"3813_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108131","author":"T Siegmund","year":"2020","unstructured":"Siegmund T, Ampudia-Blasco FJ, Schnell O (2020) Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2020.108131","journal-title":"Diabetes Res Clin Pract"},{"key":"3813_CR31","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0605","author":"S Boeder","year":"2024","unstructured":"Boeder S, Davies MJ, McGill JB et al (2024) Beta-hydroxybutyrate levels and risk of diabetic ketoacidosis in adults with Type 1 Diabetes treated with sotagliflozin. Diabetes Technol Ther. https:\/\/doi.org\/10.1089\/dia.2023.0605","journal-title":"Diabetes Technol Ther"},{"key":"3813_CR32","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verg\u00e8s B (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 40:S28\u2013S34. https:\/\/doi.org\/10.1016\/S1262-3636(14)72693-X","journal-title":"Diabetes Metab"},{"key":"3813_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K (2016) Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 7:135\u2013138. https:\/\/doi.org\/10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"3813_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.tem.2015.05.011","volume":"26","author":"RG Kibbey","year":"2015","unstructured":"Kibbey RG (2015) SGLT-2 inhibition and glucagon: cause for alarm? Trends Endocrinol Metab 26:337\u2013338. https:\/\/doi.org\/10.1016\/j.tem.2015.05.011","journal-title":"Trends Endocrinol Metab"},{"key":"3813_CR35","doi-asserted-by":"publisher","first-page":"e242744","DOI":"10.1001\/jamanetworkopen.2024.2744","volume":"7","author":"MM Umapathysivam","year":"2024","unstructured":"Umapathysivam MM, Morgan B, Inglis JM et al (2024) SGLT2 inhibitor-associated ketoacidosis vs Type 1 diabetes-associated ketoacidosis. JAMA Netw Open 7:e242744\u2013e242744. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.2744","journal-title":"JAMA Netw Open"},{"key":"3813_CR36","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT et al (2016) American Association of clinical endocrinologists and American College of endocrinology position statement on the Association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22:753\u2013762. https:\/\/doi.org\/10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"key":"3813_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12916-024-03254-w","volume":"22","author":"F Sebastian-Valles","year":"2024","unstructured":"Sebastian-Valles F, Mart\u00ednez-Alfonso J, Arranz Martin JA et al (2024) Impact of socioeconomic status on chronic control and complications of Type 1 Diabetes mellitus in users of glucose flash systems: a follow-up study. BMC Med 22:37. https:\/\/doi.org\/10.1186\/s12916-024-03254-w","journal-title":"BMC Med"},{"key":"3813_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jcjd.2022.02.008","volume":"46","author":"MK Talbo","year":"2022","unstructured":"Talbo MK, Katz A, Dostie M et al (2022) Associations between socioeconomic status and patient experience with Type 1 Diabetes management and complications: cross-sectional analysis of a Cohort from Qu\u00e9bec, Canada. Can J Diabetes 46:569\u2013577. https:\/\/doi.org\/10.1016\/j.jcjd.2022.02.008","journal-title":"Can J Diabetes"},{"key":"3813_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.endinu.2019.09.007","volume":"67","author":"RA Jim\u00e9nez-Castillo","year":"2020","unstructured":"Jim\u00e9nez-Castillo RA, Carrizales-Sep\u00falveda EF, Rom\u00e1n-Montalvo MA et al (2020) Clinical outcomes and biochemical characteristics of a Hispanic cohort of patients with diabetic ketoacidosis: 10-Year experience in an emergency department. Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n 67:216\u2013218. https:\/\/doi.org\/10.1016\/j.endinu.2019.09.007","journal-title":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"},{"key":"3813_CR40","unstructured":"Escobedo RR (2011) Los autores declaran que no existe ning\u00fan conflicto de intereses. Diabetes mellitus"},{"key":"3813_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13098-024-01357-1","volume":"16","author":"M Ahangar Davoodi","year":"2024","unstructured":"Ahangar Davoodi M, Zamanian M, Balali B (2024) Increased incidence of the Type 1 Diabetes and diabetic ketoacidosis severity in children during COVID-19 pandemic. Diabetol Metab Syndr 16:121. https:\/\/doi.org\/10.1186\/s13098-024-01357-1","journal-title":"Diabetol Metab Syndr"},{"key":"3813_CR42","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.2337\/dc17-1583","volume":"41","author":"VW Zhong","year":"2018","unstructured":"Zhong VW, Juhaeri J, Mayer-Davis EJ (2018) Trends in Hospital Admission for diabetic ketoacidosis in adults with Type 1 and Type 2 Diabetes in England, 1998\u20132013: a retrospective cohort study. Diabetes Care 41:1870\u20131877. https:\/\/doi.org\/10.2337\/dc17-1583","journal-title":"Diabetes Care"},{"key":"3813_CR43","doi-asserted-by":"crossref","unstructured":"Gershengorn HB, Iwashyna TJ, Cooke CR, et al (2012) Variation in use of intensive care for adults with diabetic ketoacidosis. Crit Care Med 40","DOI":"10.1097\/CCM.0b013e31824e9eae"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03813-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:54:11Z","timestamp":1743324851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03813-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03813-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4802040\/v1","asserted-by":"object"}]},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Research Ethics Committee of Hospital de La Princesa, Madrid, (Study Number: 5554\u201306\/24),) approved this study and waived informed consent from patients. The research was conducted according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}